Partners

Atani is the preferred partner for bringing U.S. and European pharmaceutical and biotech companies’ products to the Japanese market. We partner as way to acquire or in-license products in all stages of development that could serve the Japanese medical community and their patients.

We are constantly looking for product opportunities for the Japanese market. As a small company we can offer to our partners rapid decision making, high prioritization of products, and effective licensing discussions. Should you consider Atani as partner for your valuable products we shall be pleased to discuss with you. Please contact us at info@atanipharma.com.

The Power to Successfully Develop and Commercialize Products

Our strategic alliance with Quintiles Transnational gives us access to its world-leading product development and commercialization expertise and resources. Quintiles is a leading provider of both development and commercialization resources in Japan, with a deep knowledge of Japanese regulatory approval and commercialization requirements. Due to our tight strategic focus on developing and commercializing cancer drugs in Japan, Atani offers a streamlined process and accelerated timelines.

Atani is Focused on its Partners

At Atani, our partners are a priority. Unlike larger companies who are developing and commercializing many products at one time, Atani is focused on bringing our select partners’ drugs to market in the most efficient and effective way. Atani is made up of multi-cultural management team who understands the Japanese culture and business environment, yet is international in its business style, allowing for more simplified, mutually beneficial partnerships.

ATANI'S PRODUCTS

THE PIPELINE

Japan represents the second largest pharmaceutical market in the world with $60 billion USD in annual sales and a high prevalence of age-related diseases, with the incidence of cancer growing at the highest rate. However, in terms of cancer therapies, Japan is a surprisingly underserved market, lagging the West in terms of new drug approvals and a cancer fatality rate that is higher than in the United States and Europe. more >>